Larvol Delta - Pfizer-has-axed-two-clinicalstage-obesity-programs-including-a-GLP1-receptor-agonist-that-came-over-in-the-10-billion-acquisition-of-Metsera

PF-07258669 - Pfizer

PF-07976016 - Pfizer

berobenatide (PF-08653944) - Pfizer

PF-08656796 - Pfizer

PF-07985631 - Pfizer

https://www.fiercebiotech.com/biotech/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-quarterly-clearout

Aug 4, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next